In this work, we comprehensively demonstrated the diverse roles of CAV1 in modulating MM cell adhesion, natural killer (NK) cell‐mediated cytotoxicity, glutaminolysis, and reactive oxygen species (ROS) homeostasis and validated CAV1 as a potent target for enhancing the efficacy of bortezomib‐ and NK cell‐based anti‐MM therapy. The gene discussed is CAV1; the disease is Miyoshi myopathy.